Human-induced Pluripotent Stem Cell Potential for Schizophrenia Therapy: A Literature Review
DOI:
https://doi.org/10.21776/ub.jkb.2025.033.03.6Keywords:
Human-induced pluripotent stem cells (HiPSCs), schizophrenia, stem cells, therapyAbstract
Schizophrenia is a severe and chronic mental disorder characterized by a neurodegenerative process. Currently, there has been no cure for schizophrenia. However, a newer significant potential for modeling and curing schizophrenia has been recognized in human-induced pluripotent stem cells (HiPSCs), which are obtained from adult somatic cell reprogramming. This study aimed to assess the potential of HiPSCs in schizophrenia by reviewing relevant scientific journals published in reputable databases such as Springer, Elsevier, Science Direct, Nature, and Pubmed, in the last 10 years. Research findings indicate that stem cells can help determine the effectiveness of antipsychotics and repair damaged neuronal cells in certain areas of the brain by transplanting programmed stem cells. The proliferative ability of neuronal cells in schizophrenia tends to decline, affecting their physiological neurogenesis. HiPSCs have the potential to return the neuronal function in schizophrenia, offering new hope in psychiatry.
Downloads
References
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition, Text Revision. Washington DC: American Psychiatric Association; 2022; p. 114-116.
2. World Health Organization (WHO). Schizophrenia. (Online) 2022. https://www.who.int/news-room/fact-sheets/detail/schizophrenia [Accesed on February 27th 2024].
3. Subramaniam M, Abdin E, Vaingankar JA, et al. Lifetime Prevalence and Correlates of Schizophrenia and Other Psychotic Disorders in Singapore. Frontiers in Psychiatry. 2021; 12: 1-10.
4. Stahl SM. Neuroscientific Basis and Practical Applications: Stahl's Essential Psychopharmacology. 5th edition. Cambridge: Cambridge University Press; 2021; p. 77-243.
5. Boland R and Verduin ML. Kaplan & Sadock's Concise Textbook of Clinical Psychiatry. 5th edition. Philadelphia: Wolters Kluwer; 2023; p. 1072-1084.
6. Potkin SG, Kane JM, Corell CU, et al. The Neurobiology of Treatment-Resistent Schizophrenia: Paths to Antipsychotic Resistence and Roadmap for Future Research. NPJ Schizophrenia. 2020; 6: 1-10.
7. Grover S, Sahoo S, Rabha A, and Koirala R. ECT in Schizophrenia: A Review of Evidence. Acta Neuropsychiatrica. 2018; 31(3): 115-127.
8. Moslem M, Olive J, and Falk A. Stem Cell Models of Schizophrenia, What Have We Learned and What is the Potential? Schizophrenia Research. 2019; 210: 3-12.
9. Yamanaka S. Pluripotent Stem Cell-Based Cell Therapy—Promise and Challenges. Cell stem cell. 2020; 27(4): 523-531.
10. Chen CC, Wang L, Plikus MV, et al. Organ-Level Quorum Sensing Directs Regeneration in Hair Stem Cell Populations. Cell. 2015; 161: 277-290.
11. Nishimura K, Doi D, Samata B, et al. Estradiol Facilitates Functional Integration of iPSC-Derived Dopaminergic Neurons into Striatal Neuronal Circuits via Activation of Integrin α5β1. Stem Cell Reports. 2016; 6: 511-524.
12. Rastgar N. Schizophrenia; Recent Cognitive and Treatment Approaches using Induced Pluripotent Stem Cells. International Clinical Neuroscience Journal. 2020; 7(4): 171-178.
13. Avior Y, Sagi I, Benvenisty N. Pluripotent Stem Cells in Disease Modelling and Drug Discovery. Nature Reviews Molecular Cell Biology. 2016; 17: 170-182.
14. Donegan JJ and Lodge DJ. Stem Cells for Improving the Treatment of Neurodevelopmental Disorders. Stem Cells and Development. 2020; 29: 1118-1130.
15. Łos MJ, Skubis A, and Ghavami S. Chapter 2—Stem Cells. In: Łos MJ, Hudecki A, and Wiecheć E (Eds). Stem Cells and Biomaterials for Regenerative Medicine. Cambridge: Academic Press; 201: pp. 5–16.
16. Zhang Y, Zhao Y, Song X, et al. Modulation of Stem Cells as Therapeutics for Severe Mental Disorders and Cognitive Impairments. Frontiers in Psychiatry. 2020; 11: 1-33.
17. Thanaskody K, Jusop AS, Tye GJ, Zaman WSWK, Dass SA, and Nordin F. MSCs vs. iPSCs: Potential in Therapeutic Applications. Frontiers in Cell and Developmental Biology. 2022; 10: 1-31.
18. Volarevic V, Markovic BS, Gazdic M, et al. Ethical and Safety Issues of Stem Cell-Based Therapy. International Journal of Medical Sciences. 2018; 15(1): 36-45.
19. Cherkashova EA, Leonov GE, Namestnikova DD, et al. Methods of Generation of Induced Pluripotent Stem Cells and Their Application for the Therapy of Central Nervous System Diseases. Bulletin of Experimental Biology and Medicine. 2020; 168(4): 566–573.
20. Polin RA, Rowitch DH, Fox WW, Abman SH, and Benittz WE. Fetal and Neonatal Physiology. 5th edition. Philadelphia: Elsevier; 2017; p. 54-75.
21. Kálmán S, Hathy E, and Réthelyi JM. A Dishful of a Troubled Mind: Induced Pluripotent Stem Cells in Psychiatric Research. Stem Cells International. 2016; 2016: 1-21.
22. Soliman MA, Aboharb F, Zeltner N, and Studer L. Pluripotent Stem Cells in Neuropsychiatric Disorders. Molecular Psychiatry. 2017; 22(9): 1241-1249.
23. Stöberl N, Maguire E, Salis E, Shaw B, Hall-Roberts H. Human iPSC-Derived Glia Models for the Study of Neuroinflammation. Journal of Neuroinflammation. 2023; 20: 1-20.
24. Liu G, David BT, Trawczynski M, and Fessler RG. Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications. Stem Cell Reviews and Reports. 2020; 16: 3-32
25. Das D, Feuer K, Wahbeh M, and Avramopoulos D. Modeling Psychiatric Disorder Biology with Stem Cells. Current Psychiatry reports. 2020; 22(5): 1-42.
26. Onitsuka T, Hirano Y, Nakazawa T, et al. Toward Recovery in Schizophrenia: Current Concepts, Findings, and Future Research Directions. Psychiatry and Clinical Neurosciences. 2022; 76(7): 282-291.
27. Iannitelli A, Quartini A, Tirassa P, and Bersani G. Schizophrenia and Neurogenesis: A Stem Cell Approach. Neuroscience and Biobehavioral Reviews. 2017; 80: 414-442.
28. Lee K, Hawi ZH, Parkington HC, et al. The Application of Human Pluripotent Stem Cells to Model the Neuronal and Glial Components of Neurodevelopmental Disorders. Molecular Psychiatry. 2020; 25: 368-378.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Jurnal Kedokteran Brawijaya
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
